Front Page News
Dr. John Kissel, Chair of Neurology at OSU Wexner Medical Center, Retires After 40 Years
Dr. John Kissel has treated patients with neuromuscular disorders from all over the United States. He specializes in spinal muscular atrophy and has been instrumental […]
Read More ›Roche Releases Community Update on Risdiplam
The following is a community update from Genentech/Roche on the risdiplam (RG7916) program. Dear SMA advocacy community, As requested, we are very pleased to share […]
Read More ›Cure SMA Awards $300,000 Grant to Umrao Monani, PhD, Columbia University
Cure SMA has awarded a $300,000 preclinical drug discovery grant to Umrao Monani, PhD, at Columbia University, for his project, ” Restoring function at the […]
Read More ›HHS Secretary, Alex Azar, Recommends Nationwide Newborn Screening for SMA
Health and Human Services Secretary Alex Azar today approved the recommendation that newborn screening for spinal muscular atrophy be implemented nationwide. This recommendation was issued […]
Read More ›SMA Newborn Screening Moves Forward in New Jersey
Earlier this month, the New Jersey State Senate Committee on Health, Human Services, and Senior Citizens unanimously approved S. 974. Introduced by Senator Troy Singleton, […]
Read More ›Thank You For a Wonderful 2018 Annual SMA Conference!
Thank you to everyone who attended the 2018 Annual SMA Conference at the Hilton Anatole Hotel in Dallas, Texas! It was an impactful weekend of […]
Read More ›Summer 2018 Issue of Compass Now Available
The summer 2018 issue of Compass is now available online. As part of our most recent round of funding, we’ve announced ten grants totaling $1,325,000 […]
Read More ›PTC Therapeutics Announces Risdiplam (RG7916) is Well Tolerated at All Dose Levels With No Drug-Related Safety Findings
On Saturday, PTC Therapeutics, Inc. announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study investigating risdiplam (RG7916) in babies […]
Read More ›Cytokinetics Presents Data from the Phase 2 Clinical Trial of Reldesemtiv (CK-2127107) in Patients with SMA at the 2018 Annual SMA Conference
Today, Cytokinetics announced data from the Phase 2 clinical study of reldesemtiv in patients with SMA, presented in an oral presentation by John W. Day, […]
Read More ›Biogen to Present New Data at the 2018 Annual SMA Conference
Yesterday, Biogen announced it will present data from its SPINRAZA clinical development program –the largest of its kind, with more than six years of data–for […]
Read More ›